20Nov 2022
Anti-acid Therapies in Idiopathic Pulmonary Fibrosis: Premature to Dismiss?

Anti-acid Therapies in Idiopathic Pulmonary Fibrosis: Premature to Dismiss?

The authors read with great interest the latest “Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults” official American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Asociación Latinoamericana de Tórax clinical practice guideline published in the May 2022 issue of the Journal. The committee addressed antacid medication and antireflux surgery in patients with idiopathic pulmonary fibrosis (IPF). The authors were surprised to see that the updated edition recommends against commencing antacid medication or anti-reflux surgery in contrast to prior versions to improve respiratory outcomes in IPF.

  • #critical care

Like

Save

Share